CRNX Crinetics Pharmaceuticals Inc

$41.61

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/2/2025

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.

Website: https://www.crinetics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1658247
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA, US
Valuation
Market Cap
$2.83B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.14
Performance
EPS
$-3.69
Dividend Yield
—
Profit Margin
0.00%
ROE
-32.00%
Technicals
50D MA
$33.29
200D MA
$47.24
52W High
$62.53
52W Low
$24.10
Fundamentals
Shares Outstanding
93M
Target Price
$75.36
Beta
0.38

CRNX EPS Estimates vs Actual

● Estimated
● Actual

CRNX News & Sentiment

Sep 28, 2025 • Motley Fool SOMEWHAT-BULLISH
Is Crinetics Pharmaceuticals Stock a Buy?
The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.
Sep 26, 2025 • Benzinga NEUTRAL
Why Is Crinetics Pharma Stock Skyrocketing Friday? - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
On Thursday, the U.S. Food and Drug Administration ( FDA ) approved Crinetics Pharmaceuticals, Inc.'s ( NASDAQ: CRNX ) Palsonify ( paltusotine ) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
Sep 26, 2025 • Benzinga SOMEWHAT-BULLISH
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday - Robo.ai ( NASDAQ:AIIO ) , Aquestive Therapeutics ( NASDAQ:AQST )
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. ( NASDAQ: CRNX ) rose sharply during Friday's session after the FDA approved PALSONIFY. Also, Baird and JMP Securities raised their respective price targets on ...
Sep 10, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common ...
Aug 21, 2025 • GlobeNewswire NEUTRAL
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia ( CAH )
SAN DIEGO, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that the U.S. Food and Drug Administration ( FDA ) granted Orphan Drug Designation ( ODD ) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone ( ACTH ) receptor ...
Aug 21, 2025 • Benzinga SOMEWHAT-BULLISH
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia ( CAH ) - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
SAN DIEGO, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. CRNX today announced that the U.S.
Sentiment Snapshot

Average Sentiment Score:

0.163
50 articles with scored sentiment

Overall Sentiment:

Bullish

CRNX Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.88
  • Estimate: $-0.89
  • Whisper: —
  • Surprise %: 1.3%
Nov 12, 2024
Sep 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.96
  • Estimate: $-0.91
  • Whisper: —
  • Surprise %: -5.5%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.08 Surprise
  • Reported EPS: $-0.94
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -9.3%
May 09, 2024
Mar 31, 2024 (Post market)
-0.12 Surprise
  • Reported EPS: $-0.93
  • Estimate: $-0.81
  • Whisper: —
  • Surprise %: -14.8%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.90
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -4.7%
Nov 07, 2023
Sep 30, 2023 (Post market)
-0.15 Surprise
  • Reported EPS: $-1.01
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -17.4%
Aug 08, 2023
Jun 30, 2023 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.94
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -9.3%
May 04, 2023
Mar 31, 2023 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.85
  • Estimate: $-0.81
  • Whisper: —
  • Surprise %: -4.9%
Feb 28, 2023
Dec 31, 2022 (Post market)
-0.02 Surprise
  • Reported EPS: $-0.84
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -2.4%

Financials